BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 237 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $703,284 | +21.7% | 113,800 | 0.0% | 0.00% | 0.0% |
| Q1 2024 | $578,104 | -15.2% | 113,800 | 0.0% | 0.00% | 0.0% |
| Q4 2023 | $681,662 | -15.4% | 113,800 | 0.0% | 0.00% | 0.0% |
| Q3 2023 | $805,704 | +0.6% | 113,800 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $801,152 | -15.6% | 113,800 | 0.0% | 0.00% | -50.0% |
| Q1 2023 | $949,092 | -55.2% | 113,800 | -38.4% | 0.00% | -50.0% |
| Q4 2022 | $2,120,356 | +1978.8% | 184,700 | +2180.2% | 0.00% | – |
| Q3 2022 | $102,000 | +3300.0% | 8,100 | +3667.4% | 0.00% | – |
| Q4 2021 | $3,000 | -99.9% | 215 | -100.0% | 0.00% | -100.0% |
| Q4 2019 | $2,585,000 | – | 749,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |